Statistics from Altmetric.com
Recently, Mahadevan recalled that infliximab and adalimumab are classified by the Food and Drug Administration as pregnancy class B agents because there is no documented human toxicity (Gut 2006;55:1198–206). If the decision to continue infliximab throughout pregnancy is made, it should be avoided during the third trimester when transplacental transfer is at its greatest.1 While there are limited data on the use of adalimumab and infliximab in pregnancy, the safety and efficacy of certolizumab during pregnancy are unknown.
We report the case of …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.